Publications – Agios Pharmaceuticals, Inc.

Year

Jun 11, 2022

Evidence of Noninferiority of Mitapivat Versus Splenectomy in Murine Hereditary Spherocytosis

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Long-term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults With Non–transfusion-dependent Alpha- or Beta-thalassemia

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Comorbidities and Complications Across Genotypes in Adult Patients With Pyruvate Kinase Deficiency: Analysis From the Peak Registry

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Mitapivat Decreases the Need for Transfusions Secondary to Poorly Tolerated Anemia and Acute Events Compared to Placebo in Patients With Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Bone Mineral Density Remains Stable in Pyruvate Kinase Deficiency Patients Receiving Long-term Treatment With Mitapivat

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Durability of Hemoglobin Response and Reduction in Transfusion Burden Is Maintained Over Time in Patients With Pyruvate Kinase Deficiency Treated With Mitapivat in a Long-term Extension Study

Source

EHA 2022 Annual Meeting

Jun 10, 2022

ACTIVATE-kidsT: Mitapivat in Children With Pyruvate Kinase Deficiency Who Are Regularly Transfused

Source

EHA 2022 Annual Meeting

Jun 10, 2022

ACTIVATE-kids: Mitapivat in Children With Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Long-term Treatment With Oral Mitapivat Is Associated With Normalization of Hemoglobin Levels in Patients With Pyruvate Kinase Deficiency

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Characterizing Iron Overload by Age in Patients Diagnosed with Pyruvate Kinase Deficiency – a Descriptive Analysis from the Peak Registry

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Mitapivat Improves Ineffective Erythropoiesis and Reduces Iron Overload in Patients With Pyruvate Kinase Deficiency

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Improvements in Patient-Reported Outcomes in Mitapivat-treated Patients With Pyruvate Kinase Deficiency: A Descriptive Analysis From the Phase 3 ACTIVATE Trial

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Systematic Literature Review of Health-related Quality of Life Burden in Patients Across the Spectrum of Thalassemia

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Pharmacokinetic Modeling and Simulation to Support Mitapivat Dose Selection Used in Pediatric Phase III Studies

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Healthcare Resource Utilization of Adult Patients With Pyruvate Kinase Deficiency: A Real World Study Using US Veterans Health Administration Data

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Pharmacodynamic Effects of AG-946, a Highly Potent Novel Activator of Pyruvate Kinase, In Ex Vivo Treatment of Red Blood Cells From Sickle Cell Disease Patients

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Follow-up Results of a Phase 2 Study Assessing the Safety and Efficacy of Mitapivat Treatment, an Oral Pyruvate Kinase Activator, for up to 60 Weeks in Subjects With Sickle Cell Disease

Source

EHA 2022 Annual Meeting

Jun 10, 2022

Adapting Patient Educational Approaches in Pyruvate Kinase Deficiency: Europe and North America Findings From the AAC Patient and Caregiver Survey

Source

EHA 2022 Annual Meeting

May 16, 2022

A Phase 1 Dose Escalation Study of the Pyruvate Kinase Activator Mitapivat (AG-348) in Sickle Cell Disease

Source

Blood

Apr 14, 2022

Mitapivat versus Placebo for Pyruvate Kinase Deficiency

Source

New England Journal of Medicine

For details on our former oncology programs, visit https://www.servier.us/.